1
|
Perlikowska R, Silva J, Alves C, Susano P, Zakłos-Szyda M, Skibska A, Adamska-Bartłomiejczyk A, Wtorek K, do Rego JC, do Rego JL, Kluczyk A, Pedrosa R. Neuroprotective and Anti-inflammatory Effects of Rubiscolin-6 Analogs with Proline Surrogates in Position 2. Neurochem Res 2024; 49:895-918. [PMID: 38117448 PMCID: PMC10901950 DOI: 10.1007/s11064-023-04070-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 09/27/2023] [Accepted: 11/16/2023] [Indexed: 12/21/2023]
Abstract
Naturally occurring peptides, such as rubiscolins derived from spinach leaves, have been shown to possess some interesting activities. They exerted central effects, such as antinociception, memory consolidation and anxiolytic-like activity. The fact that rubiscolins are potent even when given orally makes them very promising drug candidates. The present work tested whether rubiscolin-6 (R-6, Tyr-Pro-Leu-Asp-Leu-Phe) analogs have neuroprotective and anti-inflammatory effects. These hypotheses were tested in the 6-hydroxydopamine (6-OHDA) injury model of human neuroblastoma SH-SY5Y and lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The determination of reactive oxygen species (ROS), mitochondrial membrane potential (MMP), Caspase-3 activity, lipid peroxidation and nitric oxide (NO) production allowed us to determine the effects of peptides on hallmarks related to Parkinson's Disease (PD) and inflammation. Additionally, we investigated the impact of R-6 analogs on serine-threonine kinase (also known as protein kinase B, AKT) and mammalian target of rapamycin (mTOR) activation. The treatment with analogs 3 (Tyr-Inp-Leu-Asp-Leu-Phe-OH), 5 (Dmt-Inp-Leu-Asp-Leu-Phe-OH) and 7 (Tyr-Inp-Leu-Asp-Leu-Phe-NH2) most effectively prevented neuronal death via attenuation of ROS, mitochondrial dysfunction and Caspase-3 activity. Peptides 5 and 7 significantly increased the protein expression of the phosphorylated-AKT (p-AKT) and phosphorylated-mTOR (p-mTOR). Additionally, selected analogs could also ameliorate LPS-mediated inflammation in macrophages via inhibition of intracellular generation of ROS and NO production. Our findings suggest that R-6 analogs exert protective effects, possibly related to an anti-oxidation mechanism in in vitro model of PD. The data shows that the most potent peptides can inhibit 6-OHDA injury by activating the PI3-K/AKT/mTOR pathway, thus playing a neuroprotective role and may provide a rational and robust approach in the design of new therapeutics or even functional foods.
Collapse
Affiliation(s)
- Renata Perlikowska
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland.
| | - Joana Silva
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, Politécnico de Leiria, 2520-630, Peniche, Portugal
| | - Celso Alves
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, ESTM, Politécnico de Leiria, 2520-614, Peniche, Portugal
| | - Patricia Susano
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, Politécnico de Leiria, 2520-630, Peniche, Portugal
| | - Małgorzata Zakłos-Szyda
- Institute of Molecular and Industrial Biotechnology, Faculty of Biotechnology and Food Sciences, Lodz University of Technology, Stefanowskiego 2/22, 90-537, Lodz, Poland
| | - Agnieszka Skibska
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Anna Adamska-Bartłomiejczyk
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Karol Wtorek
- Department of Biomolecular Chemistry, Faculty of Medicine, Medical University, Mazowiecka 6/8, 92-215, Lodz, Poland
| | - Jean-Claude do Rego
- Platform of Behavioural Analysis (SCAC), Inserm US51 - CNRS UAR2026 HeRaCLes, Institute For Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France
| | - Jean-Luc do Rego
- Platform of Behavioural Analysis (SCAC), Inserm US51 - CNRS UAR2026 HeRaCLes, Institute For Research and Innovation in Biomedicine (IRIB), University of Rouen Normandy, Rouen, France
| | - Alicja Kluczyk
- Faculty of Chemistry, University of Wroclaw, 50-383, Wroclaw, Poland
| | - Rui Pedrosa
- MARE-Marine and Environmental Sciences Centre, ARNET - Aquatic Research Network, ESTM, Politécnico de Leiria, 2520-614, Peniche, Portugal
| |
Collapse
|
2
|
Nicol M, Lahaye E, El Mehdi M, do Rego JL, do Rego JC, Fetissov SO. Lactobacillus salivarius and Lactobacillus gasseri supplementation reduces stress-induced sugar craving in mice. EUROPEAN EATING DISORDERS REVIEW 2023. [PMID: 37365682 DOI: 10.1002/erv.3004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 04/18/2023] [Accepted: 06/12/2023] [Indexed: 06/28/2023]
Abstract
OBJECTIVE Increased intake of sweets or sugar craving may occur in response to chronic stress representing a risk factor for development of eating disorders and obesity. However, no safe treatment of stress-induced sugar craving is available. In this study we analysed effects of two Lactobacillus strains on food and sucrose intake in mice before and during their exposure to a chronic mild stress (CMS). RESEARCH METHODS & PROCEDURES C57Bl6 mice were gavaged daily for 27 days with a mix of L. salivarius (LS) LS7892 and L. gasseri (LG) LG6410 strains or with 0.9% NaCl as a control. Following 10 days of gavage, mice were individually placed into the Modular Phenotypic cages, and after 7 days of acclimation were exposed to a CMS model for 10 days. Food, water and 2% sucrose intakes as well as meal pattern were monitored. Anxiety and depressive-like behaviour were analysed by standard tests. RESULTS Exposure of mice to CMS was accompanied by increased size of sucrose intake in the control group likely reflecting the stress-induced sugar craving. A consistent, about 20% lower total sucrose intake, was observed in the Lactobacilli-treated group during stress which was mainly due to a reduced number of intakes. Lactobacilli treatment also modified the meal pattern before and during the CMS, showing a decrease of meal number and an increase of meal size with a tendency of reduced total daily food intake. Mild anti-depressive behavioural effects of the Lactobacilli mix were also present. CONCLUSION Supplementation of mice with LS LS7892 and LG LG6410 decreases sugar consumption suggesting a potential utility of these strains against stress-induced sugar craving.
Collapse
Affiliation(s)
- Marion Nicol
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| | - Emilie Lahaye
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| | - Mouna El Mehdi
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| | - Jean-Luc do Rego
- University of Rouen Normandie, Inserm US51, CNRS UAR2026, Animal Behavioral Platform SCAC-HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
| | - Jean-Claude do Rego
- University of Rouen Normandie, Inserm US51, CNRS UAR2026, Animal Behavioral Platform SCAC-HeRacLeS, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
| | - Serguei O Fetissov
- Regulatory Peptides - Energy Metabolism and Motivated Behavior Team, Neuroendocrine, Endocrine and Germinal Differentiation and Communication Laboratory, Inserm UMR 1239, University of Rouen Normandie, Rouen, France
| |
Collapse
|
3
|
McHugh KL, Kelly JP. Modulation of the central opioid system as an antidepressant target in rodent models. PROGRESS IN BRAIN RESEARCH 2018; 239:49-87. [DOI: 10.1016/bs.pbr.2018.07.003] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
4
|
Salaga M, Mokrowiecka A, Zielinska M, Malecka-Panas E, Kordek R, Kamysz E, Fichna J. New Peptide Inhibitor of Dipeptidyl Peptidase IV, EMDB-1 Extends the Half-Life of GLP-2 and Attenuates Colitis in Mice after Topical Administration. J Pharmacol Exp Ther 2017; 363:92-103. [PMID: 28724693 DOI: 10.1124/jpet.117.242586] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2017] [Accepted: 07/12/2017] [Indexed: 12/20/2022] Open
Abstract
Protease inhibition has become a possible new approach in inflammatory bowel disease (IBD) therapy. A serine exopeptidase, dipeptidyl peptidase IV (DPP IV), is responsible for the inactivation of incretin hormone, glucagon-like peptide 2 (GLP-2), a potent stimulator of intestinal epithelium regeneration and growth. Recently, we showed that the novel peptide analog of endomorphin-2, Tyr-Pro-D-ClPhe-Phe-NH2 (EMDB-1) is a potent blocker of DPP IV and has an inhibitory effect on gastrointestinal (GI) smooth muscle contractility. The aim of this study was to characterize the anti-inflammatory effect and mechanism of action of EMDB-1 in the mouse GI tract. We used two models of experimental colitis (induced by TNBS and DSS). The anti-inflammatory effect of EMDB-1 was assessed by the determination of macroscopic score, ulcer score, colonic wall thickness, as well as myeloperoxidase activity. Additionally, we measured the expression of GLP-2, GLP2R, and DPP IV in the colon of control and colitic animals treated with the test compound. The expression of GLP-2 and GLP2R in the serum and colon of IBD patients and healthy control subjects has been assessed. We showed that EMDB-1 elevates the half-life of GLP-2 in vitro and attenuates acute, semichronic, and relapsing TNBS as well as DSS-induced colitis in mice after topical administration. The anti-inflammatory action of EMDB-1 is associated with changes in the level of colonic GLP-2 but not DPP IV expression. Our results validate DPP IV as a pharmacological target for the anti-IBD drugs, and its inhibitors based on natural substrates, such as EMDB-1, have the potential to become valuable anti-inflammatory therapeutic agents.
Collapse
Affiliation(s)
- Maciej Salaga
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| | - Anna Mokrowiecka
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| | - Marta Zielinska
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| | - Ewa Malecka-Panas
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| | - Radzislaw Kordek
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| | - Elzbieta Kamysz
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| | - Jakub Fichna
- Department of Biochemistry, Department of Digestive Tract Diseases, Department of Pathology, Faculty of Medicine, Medical University of Lodz, Lodz, Poland (M.S., A.M., M.Z., E.M.P., R.K., J.F.); and Department of Molecular Biotechnology, Faculty of Chemistry, University of Gdansk, Gdansk, Poland (E.K.)
| |
Collapse
|
5
|
Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. Naunyn Schmiedebergs Arch Pharmacol 2015; 388:1069-77. [PMID: 26068703 PMCID: PMC4561081 DOI: 10.1007/s00210-015-1142-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2015] [Accepted: 06/02/2015] [Indexed: 01/20/2023]
Abstract
Calea zacatechichi Schltdl. (Asteraceae alt. Compositae) is a Mexican plant commonly used in folk medicine to treat respiratory and gastrointestinal (GI) disorders. The objective of this study is to characterize the effect of C. zacatechichi extracts in mouse models mimicking the symptoms of irritable bowel syndrome (IBS). Powdered C. zacatechichi herb (leaves, stems, and flowers) was extracted with methanol. Methanolic extract was filtered and evaporated giving methanolic fraction. The residue was extracted with dichloromethane (DCM). Methanolic and DCM (200 mg/kg, per os) extracts were screened for their effect on GI motility in several in vitro tests, and the antidiarrheal and antinociceptive effects were assessed using mouse models. The influence of the DCM extract on motoric parameters and exploratory behaviors was also assessed. Finally, the composition of C. zacatechichi DCM extract was qualitatively analyzed using liquid chromatography-mass spectrometry (LC-MS) method. C. zacatechichi DCM extract significantly inhibited the contractility of mouse colon in vitro (IC50 = 17 ± 2 μg/ml). Administration of the DCM extract in vivo (200 mg/kg, per os) significantly prolonged the time of whole GI transit (46 ± 1 vs. 117 ± 27 min for control and DCM-treated animals, respectively; P = 0.0023), inhibited hypermotility, and reduced pain in mouse models mimicking functional GI disorders. Our findings suggest that constituents of the C. zacatechichi DCM extract exhibit antidiarrheal and analgesic activity. The extract may thus become an attractive material for isolation of compounds that may be used as a supplementary treatment for pain and diarrhea associated with IBS in the future.
Collapse
|
6
|
Zielińska M, Chen C, Mokrowiecka A, Cygankiewicz AI, Zakrzewski PK, Sałaga M, Małecka-Panas E, Wlaź P, Krajewska WM, Fichna J. Orally administered novel cyclic pentapeptide P-317 alleviates symptoms of diarrhoea-predominant irritable bowel syndrome. J Pharm Pharmacol 2014; 67:244-54. [DOI: 10.1111/jphp.12335] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2014] [Accepted: 09/09/2014] [Indexed: 12/20/2022]
Abstract
Abstract
Objective
The aim of our study was to characterize the effect of P-317, a novel cyclic derivative of morphiceptin, on gastrointestinal (GI) motility and abdominal pain in mouse models mimicking symptoms of diarrhoea-predominant irritable bowel syndrome (IBS-D).
Methods
The effect of P-317 on mouse intestinal motility was characterized in vitro and in vivo in physiological and pathopysiological conditions. The antinociceptive action of P-317 was characterized in the mustard oil-induced abdominal pain model and the writhing test. Locomotor activity and grip-strength tests were used to evaluate the effect of P-317 in the central nervous system (CNS). To translate our study to clinical conditions, the semi-quantitative expression of μ-opioid receptors (MOP) and κ-opioid receptors (KOP) messenger RNA (mRNA) in human colonic samples from IBS-D patients was quantified.
Key findings
In vitro, P-317 (10−10–10−6 M) inhibited colonic and ileal smooth muscle contractions in a concentration-dependent, β-funaltrexamine and nor-binaltorphimine-reversible manner. In vivo, P-317 (0.1 mg/kg, i.p. and 1 mg/kg, p.o.) inhibited GI transit, displayed a potent antinociceptive action in abdominal pain tests and did not influence the CNS.
Conclusion
P-317 produced a potent analgesic and antidiarrhoeal action in the mouse GI tract after oral administration. Given lower expression of MOP and KOP mRNA in IBS-D patients, P-317 is a promising peptide-based drug candidate for IBS-D therapy.
Collapse
Affiliation(s)
- Marta Zielińska
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
| | - Chunqiu Chen
- Department of Gastroenterological Surgery, Tenth People’s Hospital of Shanghai, School of Medicine, Tongji University, Shanghai, China
| | - Anna Mokrowiecka
- Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
| | - Adam I Cygankiewicz
- Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Piotr K Zakrzewski
- Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Maciej Sałaga
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
| | - Ewa Małecka-Panas
- Department of Digestive Tract Diseases, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
| | - Piotr Wlaź
- Department of Animal Physiology, Faculty of Biology and Biotechnology, Maria Curie-Sklodowska University, Lublin, Poland
| | - Wanda M Krajewska
- Department of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland
| | - Jakub Fichna
- Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland
- Department of Gastroenterological Surgery, Tenth People’s Hospital of Shanghai, School of Medicine, Tongji University, Shanghai, China
| |
Collapse
|
7
|
Perlikowska R, Piekielna J, Mazur M, Koralewski R, Olczak J, do Rego JC, Fichna J, Modranka J, Janecki T, Janecka A. Antinociceptive and antidepressant-like action of endomorphin-2 analogs with proline surrogates in position 2. Bioorg Med Chem 2014; 22:4803-9. [DOI: 10.1016/j.bmc.2014.06.056] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2014] [Revised: 06/23/2014] [Accepted: 06/30/2014] [Indexed: 10/25/2022]
|
8
|
Varamini P, Toth I. Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain. Front Pharmacol 2013; 4:155. [PMID: 24379782 PMCID: PMC3862115 DOI: 10.3389/fphar.2013.00155] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2013] [Accepted: 11/27/2013] [Indexed: 12/29/2022] Open
Abstract
Endomorphins are endogenous opioid peptides that cause potent antinociception in rodent models of acute and neuropathic pain with less undesirable side effects than opioid alkaloids. However, endomorphins are poorly suited to clinical applications because of low membrane permeability and a susceptibility to enzymatic degradation. Glycosylation and lipidation have proven to be two of the most robust approaches for the generation of new therapeutic endomorphin derivatives. Conjugation with lipoamino acids (LAA) confers an amphipathic character to the peptide, which improved interaction between the peptide and the lipid bilayer of the cell membranes, increasing permeability. Glycosylation can also improve peptide stability and blood brain barrier (BBB) transport. It is believed that an endocytotic mechanism (transcytosis) is responsible for the systemic delivery of water-soluble glycopeptides. This review discusses the application of glycosylation and lipidation strategies to improve the drug-like properties of endomorphins. Pharmacologically active endomorphin analogs with less adverse effects are also discussed.
Collapse
Affiliation(s)
- Pegah Varamini
- Medicinal Chemistry Department, School of Chemistry and Molecular Biosciences, The University of Queensland Brisbane, QLD, Australia
| | - Istvan Toth
- Medicinal Chemistry Department, School of Chemistry and Molecular Biosciences, The University of Queensland Brisbane, QLD, Australia ; Medicinal Chemistry Department, School of Pharmacy, The University of Queensland Brisbane, QLD, Australia
| |
Collapse
|
9
|
Abstract
This paper is the thirty-fourth consecutive installment of the annual review of research concerning the endogenous opioid system. It summarizes papers published during 2011 that studied the behavioral effects of molecular, pharmacological and genetic manipulation of opioid peptides, opioid receptors, opioid agonists and opioid antagonists. The particular topics that continue to be covered include the molecular-biochemical effects and neurochemical localization studies of endogenous opioids and their receptors related to behavior (Section 2), and the roles of these opioid peptides and receptors in pain and analgesia (Section 3); stress and social status (Section 4); tolerance and dependence (Section 5); learning and memory (Section 6); eating and drinking (Section 7); alcohol and drugs of abuse (Section 8); sexual activity and hormones, pregnancy, development and endocrinology (Section 9); mental illness and mood (Section 10); seizures and neurologic disorders (Section 11); electrical-related activity and neurophysiology (Section 12); general activity and locomotion (Section 13); gastrointestinal, renal and hepatic functions (Section 14); cardiovascular responses (Section 15); respiration (Section 16); and immunological responses (Section 17).
Collapse
Affiliation(s)
- Richard J Bodnar
- Department of Psychology and Neuropsychology Doctoral Sub-Program, Queens College, City University of New York, Flushing, NY 11367, United States.
| |
Collapse
|